EPZM - Epizyme, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.27
+0.26 (+2.60%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.01
Open10.06
Bid0.00 x 1200
Ask0.00 x 800
Day's Range9.88 - 10.27
52 Week Range5.14 - 16.59
Volume323,007
Avg. Volume647,841
Market Cap934.946M
Beta (3Y Monthly)2.05
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire

    Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth

    In conjunction with the new appointments, Beth Seidenberg, M.D., who has served on the company's board of directors since its founding in 2007, will step down from her position. “I am thrilled to welcome Grant and Vicky to our board as we work to execute our Vision 2020, which includes bringing tazemetostat to market for both solid tumors and hematologic malignancies and advancing three new programs into clinical development,” said Robert Bazemore, president and chief executive officer of Epizyme. “Grant’s commercial expertise will be invaluable as we finalize our plans to launch tazemetostat, and Vicky’s past experience as head of biology at Epizyme, along with her extensive drug discovery background, will be critical as we expand our internal pipeline.

  • Business Wire

    Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory Follicular Lymphoma

    The data show that tazemetostat demonstrated meaningful clinical activity and was generally well tolerated in both patients with EZH2 activating mutations and those with wild-type EZH2. The data will be presented today in an oral presentation entitled “Interim update from a Phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma” at the International Conference on Malignant Lymphoma (ICML) by Franck Morschhauser, M.D., Ph.D., Centre Hospitalier Régional Universitaire de Lille, France, an investigator in the Phase 2 trial.

  • Business Wire

    Epizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data

    Epizyme, Inc. (EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call on Friday, June 21, 2019 at 8:30 a.m. ET to discuss updated data from an ongoing Phase 2 study of its lead candidate, tazemetostat, as a monotherapy for patients with relapsed or refractory follicular lymphoma. The data, which will be from a recent June 2019 data cutoff date, will be reported in an oral presentation by Franck Morschhauser, M.D., Ph.D., Centre Hospitalier Régional Universitaire and study investigator, at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.

  • Business Wire

    Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting

    The data will be presented today in an oral presentation entitled “Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients with epithelioid sarcoma” at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting by Silvia Stacchiotti, M.D., Fondazione IRCCS Istituto Nazionale Tumori, Milan, and an investigator in the Phase 2 clinical trial. In July 2017, Epizyme completed enrollment of 62 patients in the epithelioid sarcoma cohort of its Phase 2 trial.

  • Business Wire

    Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma

    Epizyme, Inc. (EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery. Tazemetostat is an oral, first-in-class, EZH2 inhibitor discovered by Epizyme and being developed for a range of cancers and treatment settings.

  • Business Wire

    Epizyme to Present at Jefferies 2019 Healthcare Conference

    Epizyme, Inc. , a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will present at the Jefferies 2019 Healthcare Conference on June 5, 2019 at 3:00 p.m.

  • Business Wire

    Epizyme Announces New Tazemetostat Clinical Data to be Presented in Oral Sessions at Multiple Upcoming Medical Meetings

    Epizyme, Inc. (EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that new data from the epithelioid sarcoma and follicular lymphoma cohorts of the company’s ongoing Phase 2 clinical trials of tazemetostat will be reported during oral presentations at medical meetings in June. Updated data from the fully enrolled cohort of epithelioid sarcoma patients in the company’s molecularly defined solid tumor program will be presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago. Updated data from the fully enrolled cohorts of patients with follicular lymphoma, both with and without EZH2 activating mutations, will be reported at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.

  • Business Wire

    Epizyme Provides Business Update and Reports First Quarter 2019 Financial Results

    Tazemetostat NDA Submissions for Epithelioid Sarcoma and Follicular Lymphoma on Track for Second Quarter and Fourth Quarter 2019, Respectively

  • Business Wire

    Epizyme Announces Closing of Concurrent Public Offerings and Full Exercise of Underwriter’s Option to Purchase Additional Shares

    Epizyme, Inc. (EPZM), a late-stage company developing novel epigenetic therapies, today announced the closing of its two concurrent underwritten public offerings of 11,500,000 shares of its common stock and 350,000 shares of its non-voting Series A Convertible Preferred Stock, which includes the full exercise by the underwriters of their separate options in each of the respective offerings to purchase additional shares at the public offering price. The public offering price of each share of common stock was $11.50 and the public offering price of each share of Series A stock was $115.00. The aggregate gross proceeds to Epizyme from the offerings, before deducting underwriting discounts and offering expenses, are $172.50 million.

  • Business Wire

    Epizyme Announces Pricing of Concurrent Public Offerings of Common Stock and Series A Preferred Stock

    Epizyme, Inc. (EPZM), a late-stage company developing novel epigenetic therapies, today announced the pricing of two concurrent underwritten public offerings of (i) 10,000,000 shares of its common stock and (ii) 304,348 shares of its non-voting Series A Convertible Preferred Stock. Epizyme anticipates the total gross proceeds from the offering (before deducting underwriting discounts and offering expenses) will be approximately $150 million, excluding any exercise of the underwriters' options to purchase additional shares and before deducting underwriting discounts and offering expenses. The public offering price of each share of common stock is $11.50 and the public offering price of each share of Series A stock is $115.00.

  • Business Wire

    Epizyme Announces Proposed Concurrent Public Offerings of Common Stock and Series A Preferred Stock

    Epizyme, Inc. (EPZM), a late-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock in two concurrent but separate underwritten public offerings. The offerings are being made by means of separate preliminary prospectus supplements and are not contingent upon each other. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock and preferred stock offered in the offering.

  • Business Wire

    Epizyme Announces Presentations at Upcoming March Investor Conferences

    Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the following March inv

  • Business Wire

    Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

    Two Successive Tazemetostat NDA Submissions for Epithelioid Sarcoma and Follicular Lymphoma on Track for 2019

  • Business Wire

    Epizyme Announces Date of Fourth Quarter and Full Year 2018 Results and Upcoming Presentation at the 8th Annual SVB Leerink Global Health Care Conference

    Fourth Quarter and Full-Year 2018 Financial Results: Management will host a conference call and webcast to discuss its fourth quarter and full year 2018 financial results and other business highlights at 8:30 a.m. ET on Tuesday, February 26, 2019. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 1088195.

  • GlobeNewswire

    New Research: Key Drivers of Growth for ON Semiconductor, Entegris, Universal, MarineMax, Epizyme, and Merrimack Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE

    These 4 Healthcare Stocks Are Making Moves

    CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals Inc (SGYP), Novavax Inc (NVAX), and Epizyme Inc (EPZM) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI) opened Friday with the Company's shares trading at $0.63 per share, well above the $0.53 close back in October, as well as steadily ahead of $0.59 per share price point from early last month.

  • Business Wire

    Epizyme Announces Registration Path for Tazemetostat for Follicular Lymphoma and Provides Pipeline Updates and 2019 Guidance

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced a comprehensive set of pipeline updates, including that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma (FL), both with and without EZH2 activating mutations. The company recently conducted a productive meeting with the U.S. Food and Drug Administration (FDA) to discuss the FL registration strategy based on the current patient population in its ongoing Phase 2 clinical trial.

  • GlobeNewswire

    Market Trends Toward New Normal in Paramount Group, Envestnet, Assurant, HubSpot, Epizyme, and Cytosorbents — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.